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Abstract
The retinoids are a family of compounds that in nature are
derived from vitamin A or pro-vitamin A carotenoids. An
essential part of the diet for mammals, vitamin A has long been
known to be essential for many organ systems in the adult.
More recently, however, they have been shown to be
necessary for function of the brain and new discoveries point
to a central role in processes ranging from neuroplasticity to
neurogenesis. Acting in several regions of the central nervous
system including the eye, hippocampus and hypothalamus,
one common factor in its action is control of biological rhythms.
This review summarizes the role of vitamin A in the brain; its
action through the metabolite retinoic acid via specific nuclear
receptors, and the regulation of its concentration through
controlled synthesis and catabolism. The action of retinoic acid
to regulate several rhythms in the brain and body, from
circadian to seasonal, is then discussed to finish with the
importance of retinoic acid in the regular pattern of sleep.
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Vitamin A is a vital component of the mammalian diet that
is delivered to tissues in the form of circulating retinol
(Fig. 1, structure 2). Retinol is metabolized to the trans-
criptionally active compound retinoic acid (RA; Fig. 1,
structure 5). That RA is a key molecule during embryonic
development is well established (Ross et al. 2000) and it is
particularly crucial during development of the central
nervous system (CNS; Maden 2002). More recently,
however, results point to an important role for RA in the
adult CNS and evidence suggests that RA mediates
neuronal plasticity (McCaffery et al. 2006; Chen et al.
2012) as well as neurogenesis in both the hippocampus
(Goodman et al. 2012) and hypothalamus (Shearer et al.
2012b). Now, a new homeostatic role is emerging for RA
as a regulator of biological rhythms within the CNS
(Fig. 2).
It is now evident that several components of the RA
signalling pathway oscillate according to photoperiodic
changes in light conditions. Increased day length leads to
enhanced retinoid signalling within the hypothalamus of the
F344 photoperiodic rat (Shearer et al. 2010). The daily
peak in melatonin synthesis by the pineal gland is known to
be reduced under vitamin A-deficient conditions in the
Japanese quail (Fu et al. 1999). In addition, polymorphisms
in the RA receptor b gene can regulate the relative
contribution of delta oscillations to slow-wave sleep (Maret
et al. 2005). These observations point to roles for RA in
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both circadian and seasonal rhythms, and also in the
cortical regulation of sleep. This review will discuss the
mechanisms that link RA with these biological rhythms
within the CNS.
The vitamin A signalling pathway
Vitamin A and related retinoid compounds (Fig. 1) have a
similar chemical structure containing a 6 carbon b-ionone
Fig. 2 Retinoic acid in the CNS regulates biological rhythms. Retinoic
acid (RA) may contribute to the regulation of circadian rhythms in the
suprachiasmatic nucleus (SCN), the central clock of the body (Meng
et al. 2011), the pineal gland (Herbert and Reiter 1985; Guillaumond
et al. 2005), which signals day/night to the rest of the body, and
peripheral clocks such as that of the hippocampus (Golini et al. 2012).
There is also considerable evidence suggesting that RA plays a crucial
role in the seasonal rhythms of energy balance in the ventromedial
hypothalamus (Anzano et al. 1979; Ross et al. 2005; Shearer et al.
2010). Rhythmic EEG oscillations in the cerebral cortex during sleep
are altered by RA signalling (Maret et al. 2005).
Fig. 1 Chemical structures of retinoid family members. b-carotene
(structure 1) is cleaved by b-carotene 15,15′-monooxygenase to form
two molecules of retinaldehyde (structure 4). The double arrow
between retinol (structure 2) and retinaldehyde (structure 4) indicates
the interconversion between the two retinoids catalyzed by retinol
dehydrogenases (RDHs) primarily RDH1 and RDH10 and dehydroge-
nase/reductase (SDR family) member 9 (DHRS9). The single arrow
between retinaldehyde (structure 4) and retinoic acid (structure 5)
indicates the irreversible oxidation catalyzed by retinaldhyde dehydro-
genase (RALDH) family members. Esterification of retinol is carried out
by lecithin:retinol acyltransferase (LRAT) or acyl-CoA:retinol acyltrans-
ferase (ARAT). The predominant retinyl ester (structure 3) is retinyl
palmitate (r = C15H31).
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ring and an isoprenoid chain termed a retinyl group.
Mammals are not able to generate vitamin A de novo and
must instead consume plant or animal sources of this dietary
nutrient. Vitamin A is vulnerable to loss through oxidation
and in animal tissues is found in the more stable form of fat-
soluble retinyl esters. Vitamin A can also be obtained from
plant food sources such as b-carotene, which can be cleaved
by the enzyme b-carotene 15,15′-monooxygenase to retinal-
dehyde (Fig. 1).
Retinol derived from either dietary source is absorbed by
cells of the intestinal mucosa where it is bound by cellular
retinol binding protein II (CRBP-II; Noy 2000). CRBP-II
then specifically directs retinol substrate to the enzyme
lecithin:retinol acyltransferase (Fig. 1; Herr and Ong 1992),
resulting in the re-esterification of retinol to retinyl esters.
These are packaged with other dietary lipids into chylomi-
crons and secreted from the intestinal mucosa into the
general circulation (Blomhoff et al. 1990). The liver is the
principal site for the storage and metabolism of retinoids.
Here, hydrolysis of retinyl esters results in the formation of
retinol which associates with retinol-binding protein (RBP;
Newcomer and Ong 2000). Binding of retinol to RBP results
in secretion of retinol-RBP into the blood plasma for
transportation to peripheral tissues (Ronne et al. 1983).
Retinoic acid synthesis
The transport of retinol in the general circulation coupled
with its lipophilic nature renders retinol available to virtually
all cells. However, not all tissues can oxidize retinol to RA;
only those with a requirement for RA will do this. The ability
of cells to synthesize RA and therefore to initiate retinoid
signalling is determined by the expression of RA synthetic
enzymes. Fig. 1 illustrates cellular RA synthesis in two
oxidative stages (Napoli 2012). Retinol is first converted to
retinaldehyde, a reversible reaction catalysed by retinol
dehydrogenases (RDHs) primarily RDH1 and RDH10 and
dehydrogenase/reductase (SDR family) member 9 (DHRS9).
Retinaldehyde is then converted to RA in an irreversible
reaction catalysed by retinaldehyde dehydrogenases
(RALDH1, 2 and 3, also called ALDH1A1, 2 and 3;
McCaffery et al. 1992; Suzuki et al. 2000).
In both mouse and human, the three isoforms of RALDH
are highly expressed by tissues of the developing embryo.
RALDH1 is specifically expressed in the dorsal retina where
RA signalling contributes to dorsoventral patterning
(McCaffery et al. 1999), and is also present in the axons
and terminals of a subset of tyrosine hydroxylase-expressing
dopaminergic neurons of the mesostriatal and mesolimbic
system. These neurons form a RA-generating projection from
the substantia nigra to the corpus striatum and nucleus
accumbens (McCaffery and Drager 1994; Jacobs et al.
2007). RALDH2 is widely expressed throughout the embryo
during development; RALDH2-/- embryos fail to develop
beyond E8.5, demonstrating the essential role of RALDH2 in
development (Niederreither et al. 1999). RALDH3 expres-
sion is confined to the ventral retina (McCaffery et al. 1992)
and the lateral ganglionic eminence of the telencephalon (Li
et al. 2000). Here, RA signalling regulates cell proliferation,
migration and fate determination (Molotkova et al. 2007;
Crandall et al. 2011).
The RALDHs are key to the function of RA in the
embryonic CNS and are strongly expressed in a variety of
locations during embryogenesis (McCaffery et al. 1992,
1999; McCaffery and Drager 1994). However, in the adult
rodent, there is a stark reduction in the number of tissues that
express RALDHs, and by implication the number of tissues
able to generate RA and participate in RA signalling. These
limited regions include the hypothalamus in which the
RALDHs are expressed in tanycytes to potentially control
hypothalamic regulation of energy balance (Shearer et al.
2010) by mechanisms that include regulation of neurogenesis
(Shearer et al. 2012b). In the hippocampus, RA is synthe-
sized from retinaldehyde by the high levels of RALDH2
expressed in the meninges immediately adjacent to the
dentate gyrus, which RA is presumed to enter by diffusion
(Goodman et al. 2012). This is possible in the rodent
hippocampus because of its relatively small size, but would
be ineffective in supplying the much larger human brain. In
the human hippocampus, high levels of all three RALDH
enzymes are expressed by the neurons themselves in both the
dentate gyrus and cornus ammonis (Fragoso et al. 2012).
This potentially provides high levels of RA in the human
hippocampus and the dynamics of RA supply in the human
brain are likely different from that in the rodent. The
discovery of widespread RA synthesis by neurons in the
human hippocampus serves to emphasize that RA is crucial
for hippocampal function in all mammalian species, regulat-
ing the neuroplasticity essential for learning and memory
(Shearer et al. 2012a).
The actions of retinoic acid – regulation of transcription
Upon synthesis, the primary action of RA is to regulate the
transcription of target genes, which is achieved through the
activation of nuclear receptors. The retinoic acid receptors
(RARa, b and c) are ligand-induced transcription factors
activated by the all-trans isomer of RA. Retinoic acid
binding to RAR results in conformational changes within the
ligand binding domain (LBD), promoting interaction with a
number of co-regulator complexes to predominantly activate,
but sometimes repress, transcription the latter also occurring
in the absence of ligand (Rochette-Egly and Germain 2009).
The RAR heterodimerizes with the retinoid X receptor
(RXRa, b and c). Although RXR can be bound by the 9-cis
isomer of RA (Chambon 1996), this isomer is present in a
very limited number of organs (Kane 2012) and given that
ligand-bound RAR can effectively promote transcription
with an RXR partner lacking bound ligand, it may commonly
function in that way.
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Retinoic acid regulation of transcription – new retinoic acid
response elements
The RAR/RXR heterodimers regulate transcription by bind-
ing to DNA elements consisting of two direct repeats of an
RGKTCA motif (R = A/G, K = G/T) traditionally viewed to
have a spacing of 1, 2 or 5 bp (DR1, DR2 and DR5;
reviewed by Bastien and Rochette-Egly 2004). In recent
years, however, techniques such as ChIP-chip and ChIP-seq
have allowed the large-scale study of DNA sequences bound
by RARs. These studies suggest that the earlier described
consensus is broadly correct, but also demonstrate the
remarkable flexibility of RARs in binding a wide variety of
sequences and suggest that the sites bound by RARs are
highly cell type-specific. DR5 was identified as the most
common RARE in MCF-7 cells (Hua et al. 2009) with a very
low frequency of RAR-bound DR2 elements, while DR2 and
DR5 were the most RAR-occupied sites in embryonic stem
(ES) cells during early RA-induced differentiation (Mahony
et al. 2011). However, other similar studies found that many
sites occupied by RARs do not fit the canonical DR1, DR2 or
DR5 consensus (Delacroix et al. 2010; Moutier et al. 2012).
In another study using RA-treated mouse ES cells and F9
cells, DR0 elements were found to be the most common site
bound by RARs (Moutier et al. 2012). DR8 was also found
to be a common site of RAR binding, occurring with a
similar frequency to DR5. Around 50% of DR8 RAREs
incorporated a third motif within the other two, forming a
compound RARE consisting of overlapping DR2 and DR0
sites. Analysis of these compound RAREs demonstrated that
RAR-RXR heterodimers are able to bind the DR0, DR2 and
DR8 elements and that DR8 sequences can act as RA-
responsive elements, but also suggested that the DR2 and
DR0 sites of the compound RAREs are preferentially
occupied relative to the DR8. Although preferentially bound,
a DR0-type RARE did not confer RA-responsiveness in a
reporter assay. Therefore, despite being the most common
site of RAR binding, DR0 RAREs do not appear to act as
independent transcriptional regulators.
Prior to this analysis, several DR0-type RAREs had been
described. In the context of the brain, one such DR0 RARE
has been identified in the promoter of glial fibrillary acidic
protein (GFAP), approximately 2.5 kb upstream of the
transcription start site (Asano et al. 2009). RA acted
synergistically with leukaemia inhibitory factor (LIF) to
induce GFAP expression during differentiation of neural
precursor cells to astrocytes, but the effect of RA in the
absence of LIF was small, supporting the observation of
Moutier et al. (2012) that DR0 RAREs do not act indepen-
dently. RA increased histone acetylation in the GFAP
promoter, facilitating the LIF-induced binding of pSTAT3,
and the synergistic effect of RA on LIF could be mimicked
using the histone deacetylase inhibitor valproic acid. Other
potential DR0-type RAREs have been identified in the promot-
ers of the rat genes encoding oxytocin (Adan et al. 1993)
and vasopressin (AVP; Burbach et al. 1993). RAR-occupied
DR0/8 elements, but not DR5s, were frequently located
along with other conserved motifs within a larger regulatory
element (Moutier et al. 2012). Therefore, RARs may act via
DR0-type RAREs as enhancers of the action of other
transcriptional regulators, perhaps through epigenetic mod-
ifications of their binding sites.
Additional actions of retinoic acid – regulation of protein
translation and kinase activity
In addition to the canonical role of RARs as transcription
factors, it is becoming increasingly apparent that RARs, in
particular RARa, can have non-genomic functions. These
mechanisms include regulation of protein translation. Cyto-
plasmic RARa regulates the translation of synaptic proteins,
including the a-amino-3-hydroxy-5-methyl-4-isoxazoleprop-
ionic acid (AMPA) receptor subunit glutamate receptor 1
(GLUR1) and RARa appears to directly bind to sequences in
the 5′UTRof theGLUR1 mRNA (Poon and Chen 2008; Chen
et al. 2008; reviewed in Chen et al. 2012). RARa interacts
with mRNAs via its LBD and the binding of RA disrupts the
interaction and relieves repression of translation. Most
recently, evidence has been published showing that, through
RARa, RA may also non-genomically regulate inhibitory
synaptic activity via the control of membrane trafficking of
GABA receptors (Sarti et al. 2013).
It is evident from such control of translation that RARs
can function in the cytoplasm, in addition to their
regulatory role to control transcription in the nucleus. A
series of reports have described an additional extranuclear
function for RARs in the control of kinase activity that can
lead to rapid cellular changes, often within minutes. During
neuronal differentiation, RARc can act in the cytoplasm to
regulate neurite outgrowth via a direct interaction with c-
SRC (Dey et al. 2007). The RARs can also function in the
plasma membrane. RARa directly interacts with phospha-
tidylinositol-3-kinase in the plasma membrane to activate
extracellular signal-regulated kinase 1/2 (ERK1/2) MAPK
signalling pathways (Masia et al. 2007). Alternatively
RARa can associate with G protein aq within lipid rafts
to activate the p38MAPK/MSK1 pathway (Piskunov and
Rochette-Egly 2012). ERK1/2 MAPK pathways are acti-
vated in neuronal cells and embryonic stem cells by RA
(Bost et al. 2002; Masia et al. 2007), while in other cells
types p38MAPK is activated by RA (Alsayed et al. 2001;
Piskunov and Rochette-Egly 2012). This latter pathway can
be upstream of activation of MSK1 (Bruck et al. 2009) and
provides one mechanism by which a rapid action by RA to
promote protein phosphorylation then feeds back to RARs
more traditional role of control of transcription. These non-
genomic and genomic mechanisms intersect as a result of
MSK1′s phosphorylation of RARa, promoting its capacity
to induce gene transcription. Overall, these non-genomic
pathways likely provide an important route by which RA
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has rapid control of cellular events such as neurite
outgrowth (Dey et al. 2007), growth cone turning (Farrar
et al. 2009) and control of neuronal differentiation (Ca~non
et al. 2004).
Retinoic acid catabolism
The concentration of RA available to activate the RAR/RXR
complex and therefore to contribute to retinoid signalling
within tissues is determined by the relative expression of
both the synthetic and degradative enzymes. Endogenous
degradation of RA is primarily via oxidation to a number of
polar metabolites including 4-oxo-RA and 4-hydroxy-RA. A
number of cytochrome P450 enzymes are able to catalyse
this reaction, including CYP2C8, CYP3A4 and CYP2C9
(Marill et al. 2000). However, the high KM values of these
reactions mean that their relative contributions to RA
metabolism in vivo are likely to be negligible (Gomaa et al.
2011).
The principal CYP450 family responsible for RA degra-
dation in vivo is CYP26. There are three known isoforms
encoded by separate genes: CYP26A1, CYP26B1 and
CYP26C1. The CYP26s sequentially oxidize RA to more
polar metabolites such as 4-hydroxy-RA and 4-oxo-RA
using oxygen and nicotinamide adenine dinucleotide phos-
phate reduced (NADPH) co-factors (McCaffery and Simons
2007; Topletz et al. 2012). In the embryo, the CYP26
enzymes play a role in determining the cellular exposure to
RA by inactivating it in cells that do not participate in
retinoid signalling, or where RA-activated gene transcription
would be detrimental to the cell, for example through the
perturbation of the developmental programme (Thatcher and
Isoherranen 2009). All three enzymes are expressed during
mammalian development in a highly regulated spatio-
temporal pattern (Kudoh et al. 2002). During development,
CYP26A1 and CYP26B1 are essential for generating an
uneven distribution of RA necessary for the development of
the hindbrain in the mouse embryo (Abu-Abed et al. 2001).
Furthermore, CYP26A1 expression in the prospective head
region of the gastrulating mouse embryo is vital for the
formation of anterior structures, as RA receptors in this
region must be in an unliganded state to allow the proper
development of the head (Ribes et al. 2006).
In the adult, CYP26A1 expression is much sparser with
only low expression found in the brain (Wang et al. 2002).
In contrast, CYP26B1 is considered a brain-specific RA-
degrading enzyme with a high level of expression found in
the adult cerebellum (Trofimova-Griffin and Juchau 2002)
and hippocampus (Abu-Abed et al. 2002). In situ hybrid-
ization analysis found at the Allen Brain Atlas database
shows an even more widespread distribution including the
cortex and amygdala (http://www.brain-map.org/).
Taken together, net RA production is determined by the
relative expression of RA synthetic and degradative enzymes
in a given tissue. A further element of control is
demonstrated by the ability of RA to induce the CYP26
enzymes and therefore limit its own production via a
negative feedback pathway (Reijntjes et al. 2005). CYP26A1
is regulated directly by RA, its promoter containing a
functional RARE (Loudig et al. 2000, 2005; Hu et al. 2008).
This is a key regulatory mechanism necessary to achieve
appropriate vitamin A homeostasis.
Retinoic acid in the regulation of circadian and
seasonal rhythms
Animals are able to anticipate change in the environment
over both the 24-h day and through the changing seasons by
the use of a variety of rhythmic systems. The 24-h circadian
clock is based on a central rhythm generator in the
suprachiasmatic nucleus (SCN), acting as a master clock
for the body, although most tissues also contain their own
peripheral clock (Dibner et al. 2010). These clocks rely on
an internal oscillation network within the cell reliant on a set
of feedback loops (Fig. 4), but entrained by daylight to keep
the rhythm synchronized with environmental day and night.
For seasonal rhythms the synchronizing cue is photoperiod,
the annual cycle of changing day length. Photoperiodic
information is then conveyed to the whole organism through
the secretion of melatonin from the pineal gland. Secretion of
melatonin at night is a continuous signal, the duration of
which reflects the length of the subjective night (Morgan and
Hazlerigg 2008).
Both systems are dependent on light: the circadian system
is entrained by daylight while photoperiodic information
relies on day length. Of course the eye is essential for both of
these and, in turn, vitamin A is the key to both eye
development and visual function. RA patterns retinal devel-
opment (McCaffery et al. 1999) while in the photoreceptors
retinaldehyde is the chromophore for visual pigment essential
for visual transduction via photoreceptors, but is also the
chromophore for melanopsin in the intrinsically photosensi-
tive retinal ganglion cells that innervate and signal to the
SCN (Palczewski 2012). The evolution of retinoid function
as part of this system may have overlapped with the
involvement of retinoids in other rhythmic systems in the
body and brain. The roles of RA in both circadian and
seasonal rhythms are outlined below.
Circadian rhythms in the suprachiasmatic nucleus and
hippocampus
RA may influence the body’s central clock as high levels of
RARa expression are found in the vasopressin-expressing
neurons of the human SCN (Meng et al. 2011) and our own
preliminary studies show RARa present in processes and cell
bodies in the SCN while mRNA transcript levels cycle with a
circadian rhythmicity (Fig. 3a, b). The function of vasopres-
sin neurons in the SCN was not clear until a recent study
demonstrated that mice lacking the V1a/V1b vasopressin
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receptors are able to adjust rapidly to phase-shifts in the
light-dark cycle, making them extremely resistant to jet lag
(Yamaguchi et al. 2013) and this was replicated by pharma-
cological blockade of V1a/b. This indicates that vasopressin
signalling in the SCN may stabilize the central circadian
clock. In a screen of nuclear receptor regulators of circadian
genes RA was found to induce expression of AVP (the
vasopressin gene), as well as the clock genes PER1 and
PER2, via an enhancer box (E-box)-dependent mechanism
(Shirai et al. 2006). PER proteins are central to the cellular
circadian rhythm through reciprocal positive and negative
feedback loops acting via dimers of CLOCK:BMAL1 and
CRY:PER (Fig. 4). The results of Shirai et al. also suggested
that RA could inhibit expression of CLOCK:BMAL1,
although only when RARa was present. This supports an
earlier study on blood vessels in which RA could inhibit
CLOCK:BMAL1 dimer transcriptional activity (as well as
that of MOP4:BMAL1), acting via a RARa:RXRa hetero-
dimer (McNamara et al. 2001). Thus, from these studies, RA
may promote CRY:PER and inhibit CLOCK:BMAL1 activ-
ity (Fig. 4).
RA may also play a role in the regulation of circadian
genes in the hippocampus, given that vitamin A deficiency
can phase shift the expression patterns of the clock gene
BMAL1 and completely abolishes the circadian expression of
PER1 (Golini et al. 2012; Navigatore-Fonzo et al. 2013).
Phase-shifting effects of RA are also evident in the capacity
of RA to alter rhythmic expression of vascular PER2 both
in vitro and in vivo (McNamara et al. 2001). Further
implying the involvement of RA in circadian control in the
hippocampus is the finding that many of the components of
the retinoid signalling pathway show a significant diurnal
oscillation (Navigatore-Fonzo et al. 2013). Of the potential
downstream elements that RA may control in the hippocam-
pus, the circadian rhythm of brain-derived neurotrophic
factor (BDNF) is disrupted in response to vitamin A
deficiency (Golini et al. 2012).
The E-box is one of the key enhancers used to control gene
expression of several of the circadian genes and is the target
of CLOCK:BMAL1. Of the genes required to transduce the
(a) (c)(b)
Fig. 3 Rhythmic retinoic acid signalling proteins in the hypothalamus.
(a) Immunohistochemistry shows that retinoic acid receptor (RAR)a
protein is present in both cell bodies and processes in the adult rat
suprachiasmatic nucleus. (b) mRNA expression of the encoding gene,
RARA, appears to oscillate through the 24-h day in the rat
suprachiasmatic nucleus. (c) Retinaldehyde dehydrogenase (RALDH)
1, the retinoic acid (RA)-synthesizing enzyme which shows seasonal
changes in rat hypothalamic tanycytes, is also strongly expressed in
ventral tanycytes in the mouse hypothalamus.
Fig. 4 The influence of retinoic acid (RA) on the circadian oscillator.
The core set of proteins that create the cellular circadian pacemaker
achieve this by forming a positive and a negative feedback loop (Ko and
Takahashi 2006). The positive loop involves a heterodimer of CLOCK:
BMAL1. These activate transcription of target genes that contain an
enhancer box (E-box) sequence, such as PER and CRY. The opposing
half of the circuit is the PER and CRY heterodimer which exerts a
repressive action on CLOCK:BMAL transcriptional activity. In addition,
not shown in the diagram, are multiple interlocked feedback loops that
likely both stabilize and provide robustness to the rhythm. These
additional loops include pathways that require retinoic acid receptor-
related orphan receptors (RORs). RA is reported to influence the
central components of the circadian feedback loop by inhibiting the
expression or activity of CLOCK/BMAL (McNamara et al. 2001; Shirai
et al. 2006) and inducing expression of PER (Shirai et al. 2006). In turn,
the genes that encode retinoic acid receptors (RAR)a, b and retinoid X
receptor (RXR)b may be regulated by CLOCK/BMAL via their E-box
sites (Navigatore-Fonzo et al. 2013).
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RA signal, perfect E-box or E-box-like sites are found in
RARA, RARB and RXRB making these genes potential
outputs of the circadian cycle (Navigatore-Fonzo et al.
2013). Conversely, RAREs were found in the promoter
regions of BMAL1 and PER1 (Golini et al. 2012), suggesting
that there may be direct transcriptional regulation of these
genes by RA (Navigatore-Fonzo et al. 2013).
Circadian cycles controlled by the pineal gland
The pineal gland receives information about day and night
from the retina via the suprachiasmatic nucleus (SCN), the
central clock that synchronizes the functions of the body.
There is some evidence favouring a role for RA signalling
in the generation of circadian rhythms by the mammalian
body clock. Nocturnal activity of arylalkylamine N-acetyl-
transferase, the rate-limiting enzyme in the synthesis of
melatonin from serotonin, is greatly reduced in the pineal
gland of vitamin A-deficient rats (Herbert and Reiter
1985), although the circadian timing of the nocturnal
increase in melatonin appeared unaffected. Expression of
RORB, which encodes a retinoid orphan receptor that
binds RA with high affinity, is increased at night in the
pineal gland (Bailey et al. 2009); genes encoding the
retinoid-binding proteins RBP3 and transthyretin (TTR) are
also expressed. RA is known to regulate the MAP kinases
and the circadian activation of ERK1/2 is lost in the pineal
of vitamin A-deficient (VAD) rats (Guillaumond et al.
2005). This function of vitamin A was found to be SCN-
dependent, but independent of the superior cervical
ganglion (SCG) neurons, raising the possibility that
blood-borne nutrients are able to alter the function of the
pineal gland.
Seasonal rhythms
Certain species display marked physiological responses to
seasonal change in body weight, food intake and reproduc-
tive status. These changes are driven by the hypothalamus
and the duration of nocturnal melatonin synthesis is the
means by which the mammalian hypothalamus determines
the season. When the night is short, the reduction in
melatonin disinhibits the release of thyroid-stimulating
hormone from the pars tuberalis of the pituitary (Ono et al.
2008), up-regulating thyroid hormone signalling in the
hypothalamus. Hypothalamic thyroid hormone signalling
downstream of melatonin appears to be crucial for seasonal
responses in birds (Yoshimura et al. 2003) and mammals
(Barrett et al. 2007; Ross et al. 2009).
There is evidence that vitamin A and RA are mediators of
seasonal changes in feeding and energy balance though their
actions in the hypothalamus. Evidence for this comes from
earlier studies showing that vitamin A deficiency in rats causes
a decrease in food intake accompanied by a rapid drop in
bodyweight which persists even after force-feeding (Anzano
et al. 1979). Also, mice lacking the RA synthesizing enzyme
RALDH1 are extremely resistant to diet-induced obesity
(Ziouzenkova et al. 2007). These two observations suggest a
pivotal role for RA in the control of energy balance and more
recently, the hypothalamus, the region of the brain control-
ling growth and feeding, has been recognized as a site of RA
action (Ross et al. 2004; Shearer et al. 2010, 2012b; Helfer
et al. 2012).
The RA synthetic enzymes RALDH1 and RALDH2 are
found in rat tanycytes (RALDH1 only in mice; Shearer et al.
2010 and Fig. 3c), cells which line the third ventricle
adjacent to the hypothalamus and are thought to be important
for the transduction of photoperiodic signals into the
hypothalamic nuclei. The tanycytes project RALDH1-
containing processes into the arcuate nucleus and the
dorsomedial hypothalamic nucleus (Shearer et al. 2012b).
RA synthesis by RALDH1/2 in the tanycytes is sensitive to
photoperiod with significantly higher levels of RA in the
hypothalamus of F344 rats maintained on summer-like long
day photoperiods relative to short days (winter; Helfer et al.
2012). Such a seasonal change in RA production has recently
been summarized by Shearer et al. (Shearer et al. 2012a).
This is in contrast to hypothalamic T3, which shows little
change with photoperiod (Ross et al. 2011).
A further indicator of the photoperiodic role of RA in the
hypothalamus has been demonstrated in Siberian hamsters
and F344 rats in which a long day photoperiod results in large
up-regulation of many genes involved in retinoid signalling,
including those encoding extracellular and intracellular
retinoid-binding proteins (STRA6, TTR, CRABP1, CRABP2,
CRBP1), retinoic acid receptors (RAR) and RA-degrading
enzymes (CYP26B1; Ross et al. 2004, 2005; Shearer et al.
2010; Helfer et al. 2012). Intriguingly, RPE65, previously
thought to be restricted to the retinal pigment epithelium of
the eye, is also expressed and photoperiodically regulated in
the cells lining the third ventricle in the rat (Helfer et al.
2012). In the retinal pigment epithelium, RPE65 catalyses the
isomerization of all-trans retinol to 11-cis retinaldehyde and
its expression may be a vestige of photoreceptor-like cells in
the mammalian hypothalamus. Deep-brain photoreceptors are
present in many non-mammalian species (Vigh et al. 2002)
and the periventricular region of the hypothalamus of birds is
known to detect light directly (Thayananuphat et al. 2007).
These changes suggest a large seasonal up-regulation of RA
signalling in the hypothalamus during periods of increased
somatic growth and feeding. Many of these changes in gene
expression precede physiological changes and, together with
the effects of vitamin A deficiency on energy balance
(Anzano et al. 1979), this implies a causative role for RA
(Ross et al. 2005).
The targets of RA in the hypothalamus are currently not
well understood. Some potential targets of RA have been
previously discussed (Shearer et al. 2012a). Recently, it has
been found that components of theWnt signalling pathway are
photoperiodically regulated in the hypothalamus of F344 rats,
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with expression of two inhibitors of Wnt signalling, DKK3
and SFRP2, increased in long day photoperiods when
hypothalamic RA levels are high (Helfer et al. 2012). Wnt
signalling and RA signalling are both involved in adult
neurogenesis in the hippocampus (Maden 2007; Inestrosa and
Arenas 2010), and there is some evidence that Wnt signalling
components are regulated by RA during neurogenesis and
neuronal differentiation (Katoh 2002; Jacobs et al. 2006). In
F9 teratocarcinoma cells, SFRP2 is specifically up-regulated
by RARc in response to RA (Su and Gudas 2008). In the
medial arcuate nucleus, the number of cells expressing nuclear
RARc, suggestive of an increase in transcriptional activity,
was increased in rats in long day photoperiods compared to
short day (Shearer et al. 2010). Such evidence hints at theWnt
signalling pathway as one mediator of RA’s action in the
hypothalamus (Helfer et al. 2012).
Vitamin A signalling in sleep regulation
A further biological rhythm in which vitamin A plays a key
role is the daily cycle of sleep. Humans spend approxi-
mately one-third of their lives sleeping, but the purpose of
this vital process remains obscure. Sleep is characterized by
measurable differences in brain activity of which slow-wave
sleep (SWS, or non-rapid eye movement, NREM, sleep)
featuring an electroencephalogram (EEG) delta oscillation
of < 2 Hz is most associated with CNS maintenance and
repair (Sei 2008). The power of the delta oscillation is a
reliable predictor of the homeostatic requirement for sleep
after an extended period of wakefulness, and is closely
related to the recovery function of sleep (Maret et al. 2005).
Indeed, Tononi and Cirelli (2006) have proposed a synaptic
homeostasis hypothesis for the purpose of the delta wave in
sleep. Briefly, wakefulness and daily activity are both linked
to synaptic potentiation in cortical circuits owing to our
interaction with the environment leading to increased
cortical activation. This synaptic potentiation is associated
with the homeostatic regulation of sleep in which increasing
length of wakefulness greatly increases the power of the
delta oscillation during sleep. When sleeping, we are not
interacting with the environment around us and this results
in a net downscaling of synaptic strength. Synaptic down-
scaling could have many benefits to brain function such as
reducing the energy expenditure of neural circuits (Atwell
and Laughlin 2001), reducing the space required for
potentiated synapses (Eyre et al. 2003), and improving the
memory function of cortical neurons during further wakeful
periods (Huber et al. 2004). There is the intriguing possi-
bility that this synaptic downscaling may be related to the
role of RA in the process of homeostatic synaptic plasticity,
which provides a homeostatic mechanism of neural circuit
adaptation (Chen et al. 2012).
A definitive role for vitamin A signalling however is
evident in the regulation of delta oscillations. This was first
proposed by Maret (Maret et al. 2005), who observed that
the relative contribution of the delta wave to SWS is
determined by the RA receptor RARb1. Moreover, vitamin A
deficiency is known to significantly reduce the power of the
delta oscillation in mice (Kitaoka et al. 2007), an effect that
is reversed by sleep deprivation. Intriguingly, this vitamin A
deficiency-induced reduction in delta power is accompanied
by decreased dopamine metabolism in the striatum, an
observation suggestive of a role for vitamin A in dopami-
nergic neurotransmission (Kitaoka et al. 2007). Indeed, the
RA antagonist LE540 induced a significant reduction in
wakefulness and delta oscillation power in mice treated over
a period of 4 weeks. This was associated with a reduction in
protein expression of the dopamine receptor D1DR in the
striatum, and also tyrosine hydroxylase in the hippocampus
(Kitaoka et al. 2011). It is possible therefore that retinoids
may reduce wakefulness indirectly via RAR interaction with
dopamine neurotransmission.
Further clues as to the involvement of vitamin A in the
regulation of delta oscillations come from the study of sleep in
mouse models of ageing. The SAMP8 senescence-accelerated
pronemouse shows age-related deterioration in the sleep/wake
cycle in comparison with the related senescence-accelerated
resistant mouse (SAMR1; Butterfield and Poon 2005). EEG
recordings from SAMP8 mice show a significantly reduced
delta power in comparison with that of the SAMR1 mouse,
accompanied by increased wakefulness, reduction in NREM
sleep and reduction in cortical acetylcholine content (Kitaoka
et al. 2010). The expression of several components of the
retinoid cascade is reduced in the hippocampus and brainstem
of the SAMP8 mouse including a highly significant reduction
in the expression of RARa in the hippocampus, suggesting
that a reduction in vitamin A signalling may be responsible in
part for the decline in sleep observed in this model. Surpris-
ingly, however, the RAR agonist AM80 does not improve
delta oscillation power, and no improvement in rapid eye
movement (REM) sleep is observed. It is likely therefore that
the SAMP8 phenotype is only partially explained by defi-
ciencies in the RAR activation (Kitaoka et al. 2010).
It is thus clear that vitamin A deficiency disrupts SWS
through interruption of the delta oscillation in mice. How-
ever, given that specific RAR activation is unable to recover
sleep abnormalities associated with age, it may be the case
that vitamin A regulates sleep indirectly via interaction with
dopamine and acetylcholine neurotransmission. Furthermore,
vitamin A signalling and the molecular clock show signif-
icant cross-regulation in the hippocampus. Given the impor-
tance of this brain region to learning and memory, vitamin A
may be an important factor in maintaining optimal molecular
performance throughout the solar day.
Conclusions
The observations described above make it clear that vitamin
A status has an influence on the mammalian biological clock,
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impacting on the body’s response to both the subjective day
and night, and also on seasonal regulation of physiology. A
key function of circannual rhythms is to anticipate favourable
times of year for seasonal behaviours such as reproduction
and hibernation, and nutrients are known to inform the clock
about the quality and availability of food in the environment.
It is clear that vitamin A is a key nutrient in this function.
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